Physician profile
Angalesia Rucker
NPI 1376953489
$8,547.09
in general payments reported to CMS, 2019-2025
21 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what 97% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,216 · 2022: $1,638 · 2023: $1,304 · 2024: $2,242 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,644 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,643.60 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,624.86 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $1,400.82 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $825.33 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $700.14 | 2021-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $650.17 | 2021-2025 | Caplyta |
| Alkermes, INC. | $583.36 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $520.40 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $519.73 | 2021-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $398.44 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $365.58 | 2022-2025 | Qelbree |
| Axsome Therapeutics, INC. | $272.94 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $191.77 | 2024-2025 | Cobenfy |
| Indivior INC. | $177.62 | 2021-2024 | Sublocade, Perseris |
| Neurocrine Biosciences, INC. | $137.12 | 2023-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $44.21 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $37.86 | 2025 | Erzofri Extended-Release |
| Noven Therapeutics, LLC | $29.79 | 2021-2022 | |
| Almatica Pharma LLC | $19.20 | 2024 | Loreev Xr |
| Corium, LLC | $18.35 | 2023 | Azstarys |
| Validus Pharmaceuticals LLC | $15.47 | 2024 | Equetro |
| Bausch Health US, LLC | $13.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angalesia Rucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.